Unicycive Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|
Revenue | $0 | $0 | $-271 |
Gross Profit | -284 | -353 | |
EBITDA | -7,401 | -20,659 | -7,697 |
EBIT | -7,288 | -20,943 | -7,779 |
Net Income | 3,930 | -20,963 | -7,798 |
Net Change In Cash | 0 | 0 | -271 |
Free Cash Flow | -6,339 | -6,462 | -4,439 |
Cash | 41,780 | 48,930 | 9,701 |
Basic Shares | 94,052 | 34,912 | 34,756 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $675 | $951 | $0 | $0 |
Gross Profit | 675 | 951 | -1 | |
EBITDA | -30,178 | -17,891 | -8,964 | -2,020 |
EBIT | -30,462 | -18,052 | -8,977 | -2,020 |
Net Income | -30,544 | -18,064 | -10,632 | -2,508 |
Net Change In Cash | 675 | 951 | 0 | 0 |
Free Cash Flow | -18,295 | -15,653 | -5,796 | -1,459 |
Cash | 9,701 | 455 | 16,579 | 0 |
Basic Shares | 24,539 | 15,057 | 14,996 | 15,246 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.05 |
2024-06-30 | $0.15 |
2024-03-31 | -$0.61 |
2023-12-31 | -$0.22 |
